Almirall ROA

Mitä Almirall tekee? The company Almirall SA is a globally operating pharmaceutical company headquartered in Barcelona, Spain. Founded in 1943 by Antonio Gallardo Ballart, the company has since become one of the leading companies in the field of dermatology and respiratory diseases. Almirall specializes in the development, manufacturing, and marketing of medications used in the treatment of skin conditions such as psoriasis or eczema, as well as respiratory diseases such as asthma or chronic bronchitis. The company focuses on close collaboration with doctors and patients to achieve the best possible therapeutic success. Almirall's business model is based on collaboration with other pharmaceutical companies to develop and bring innovative medications to the market. The company has its own research and development departments and also conducts clinical trials to test the safety and efficacy of new medications. Additionally, Almirall operates its own network of distribution and marketing partners to distribute its products worldwide. Almirall is organized into three divisions: dermatology, respiratory diseases, and other therapeutic areas. The dermatology division includes the development and marketing of medications for the treatment of skin conditions such as psoriasis and eczema. Some examples of products in this division are Skilarence, a medication for the treatment of moderate to severe psoriasis, and Kigozi, a topical medication for the treatment of atopic dermatitis. The respiratory diseases division includes the development and marketing of medications for the treatment of asthma and chronic bronchitis. The company offers a wide range of medications in this area that can be used in inhalation or tablet therapy. Some of the well-known products in this division are Alvesco, an inhaled corticosteroid for the treatment of asthma, and Ebastel, a medication for the treatment of allergic reactions. In other therapeutic areas, Almirall is involved in the development of new medications for the treatment of diseases such as ulcerative colitis or schizophrenia. For example, the company has developed Sativex, a cannabis-based medication for the treatment of multiple sclerosis-related spasticity, which is already approved in several countries. Throughout its history, Almirall has received numerous awards and recognition, including for the development of innovative medications and its work in the field of sustainability and corporate social responsibility. Through its commitment to research and development and collaboration with other pharmaceutical companies, Almirall will continue to play an important role in the global pharmaceutical industry market. Almirall on yksi Eurpooliin suosituimmista yhtiöistä.